Related Experiment Video

Updated: Jul 23, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K

Serum IL-38 Level Was Associated with Incidence of MACE in the STEMI Patients

Chengbo Lu1, Fanghui Zhou2, Huimin Xian3

  • 1Department of Cardiology, 1st Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang, People's Republic of China.

International Journal of General Medicine
|July 19, 2023
PubMed

Insights

Low serum interleukin-38 (IL-38) levels are linked to major adverse cardiovascular events (MACE) in ST-elevation myocardial infarction (STEMI) patients. This finding suggests IL-38 may be a predictive biomarker for cardiovascular outcomes post-STEMI.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biomarker Discovery

Background:

  • The prognostic role of interleukin-38 (IL-38) in ST-elevation myocardial infarction (STEMI) is not well-established.
  • Understanding IL-38's association with adverse cardiovascular events is crucial for risk stratification.

Purpose of the Study:

  • To investigate the relationship between serum IL-38 levels and the occurrence of major adverse cardiovascular events (MACE) in STEMI patients.
  • To determine if IL-38 can serve as a predictive biomarker for MACE in this population.

Main Methods:

  • A cohort of 589 STEMI patients was analyzed.
  • Serum IL-38 levels were measured and patients were categorized into high and low IL-38 groups.
  • Follow-up was conducted for a median of 720 days to assess MACE incidence.

Main Results:

  • STEMI patients exhibited significantly lower plasma IL-38 levels compared to stable angina (SAP) patients.
  • The incidence of MACE was substantially higher in the low IL-38 group (23.7%) versus the high IL-38 group (7.8%).
  • Low plasma IL-38 levels were identified as an independent predictor of MACE (OR = 0.90).

Conclusions:

  • Low serum IL-38 levels are independently associated with an increased risk of MACE in STEMI patients.
  • IL-38 may represent a novel biomarker for predicting adverse cardiovascular outcomes following STEMI.
Abstract

Keywords:
IL-38MACESAPSTEMIinflammatory response

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
31
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
21
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
201
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12